Tempest Therapeutics (TPST) Operating Margin (2015 - 2018)
Tempest Therapeutics (TPST) posted Operating Margin of 14192.73% for Q3 2018, down 130.57% sequentially from 6155.56% in Q2 2018, and up 260370.0% YoY from N/an in Q3 2017.
Tempest Therapeutics (TPST) Operating Margin (2015 - 2018) Analysis & Trends
Tempest Therapeutics has reported Operating Margin for 4 years, with the latest figure at 14192.73% in Q3 2018.
- Quarterly Operating Margin rose 260370.0% year-over-year to 14192.73% in Q3 2018, while the trailing twelve-month figure through Sep 2018 was 20266.67% (down 42377.0% YoY) and the FY2017 annual result came in at 28585.08%, down 1617896.0% from the prior year.
- Operating Margin slipped to 14192.73% in Q3 2018 per TPST's latest filing, from 6155.56% in the prior quarter.
- Over five years, Operating Margin peaked at 6155.56% in Q2 2018 and troughed at 112086.67% in Q1 2015.
- A 4-year average of 26210.66% and a median of 16796.43% in 2017 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2016 and 2017: Operating Margin soared 9740242 bps in 2016, then slumped 2811185 bps in 2017.
- Over 4 years, Operating Margin stood at 12891.72% in 2015, then slumped by 43 bps to 18485.95% in 2016, then tumbled by 152 bps to 46597.8% in 2017, then soared by 70 bps to 14192.73% in 2018.
- According to Business Quant data, Operating Margin over the past three periods registered 14192.73%, 6155.56%, and 6549.25% for Q3 2018, Q2 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -14,192.73% |
| Jun 30, 2018 | -6,155.56% |
| Mar 31, 2018 | -6,549.25% |
| Dec 31, 2017 | -46,597.80% |
| Sep 30, 2017 | -16,796.43% |
| Jun 30, 2017 | -21,345.24% |
| Mar 31, 2017 | -23,153.97% |
| Dec 31, 2016 | -18,485.95% |
| Sep 30, 2016 | -9,626.40% |
| Jun 30, 2016 | -9,651.32% |
| Mar 31, 2016 | -14,684.25% |
| Dec 31, 2015 | -12,891.72% |
| Sep 30, 2015 | -23,696.00% |
| Jun 30, 2015 | -57,246.67% |
| Mar 31, 2015 | -112,086.67% |